These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35653850)

  • 1. Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
    Steidl C; Aroldi A; Mologni L; Crespiatico I; Fontana D; Mastini C; Fumagalli M; Perfetti P; Borin L; Valentini C; Piazza R; Gambacorti-Passerini C
    Leuk Res; 2022 Jul; 118():106861. PubMed ID: 35653850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
    Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
    Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An NGS based MRD evaluation from acute myeloid leukemia patients.
    Chen B; Wang L; Wang Z; Zhang H; Chen L; Zhang L; Li J; Yan X; Zhao M; Lin Y; Ru K
    Int J Lab Hematol; 2023 Jun; 45(3):353-359. PubMed ID: 36751002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
    Álvarez N; Martín A; Dorado S; Colmenares R; Rufián L; Rodríguez M; Giménez A; Carneros L; Sanchez R; Carreño G; Rapado I; Heredia Y; Martínez-López J; Barrio S; Ayala R
    Front Immunol; 2024; 15():1252258. PubMed ID: 38938565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
    Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
    PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Shapiro RM; Kim DDH
    Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
    Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Tools for Diagnosis and Monitoring of AML.
    Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
    Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
    Hughes CFM; Gallipoli P; Agarwal R
    Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
    Yu T; Chi J; Wang L
    Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of next-generation sequencing in acute myeloid leukemia.
    Llop M; Sargas C; Barragán E
    Curr Opin Oncol; 2022 Nov; 34(6):723-728. PubMed ID: 36102349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
    Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
    Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
    Heuser M; Heida B; Büttner K; Wienecke CP; Teich K; Funke C; Brandes M; Klement P; Liebich A; Wichmann M; Neziri B; Chaturvedi A; Kloos A; Mintzas K; Gaidzik VI; Paschka P; Bullinger L; Fiedler W; Heim A; Puppe W; Krauter J; Döhner K; Döhner H; Ganser A; Stadler M; Hambach L; Gabdoulline R; Thol F
    Blood Adv; 2021 May; 5(9):2294-2304. PubMed ID: 33929500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.
    Stasik S; Burkhard-Meier C; Kramer M; Middeke JM; Oelschlaegel U; Sockel K; Ehninger G; Serve H; Müller-Tidow C; Baldus CD; Röllig C; Bornhäuser M; Platzbecker U; Thiede C
    Blood Adv; 2022 Jun; 6(11):3294-3303. PubMed ID: 35320339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.